ArticleFrontiers in immunology2026
Prognosis and risk factors for pathological non-response to neoadjuvant chemoimmunotherapy in locally advanced esophageal squamous cell carcinoma.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Neoadjuvant chemotherapy combined with immunotherapy (NACI) is promising for treating locally advanced esophageal squamous cell carcinoma (LA-ESCC), yet a subset of patients exhibit a pathological non-response (pNR). The prognosis and risk factors for pNR to NACI remain unclear. Methods: We retrospectively analyzed 253 patients with LA-ESCC who received NACI followed by surgery between 2020 and 2023. The immune checkpoint inhibitors (ICIs), which included pembrolizumab (200 mg), camrelizumab (200 mg), tislelizumab (200 mg), sintilimab (200 mg), nivolumab (200 mg), and toripalimab (200 mg), were administered intravenously once every three weeks. Patients with >50% residual viable tumor cells (Becker TRG3) were classified as having a pNR, while the others were classified as having a pathological response (pR). Survival and recurrence patterns were compared between the two groups. Risk factors associated with pNR and prognosis were identified. Results: The pNR rate was 39.5% (100/253). Compared with the pR group, the pNR group had significantly worse 3-year overall survival (OS) (58.2% vs. 75.8%, P = 0.001) and disease-free survival (DFS) (46.1% vs. 65.5%, P = 0.001), with higher rates of locoregional (13.0% vs. 4.6%, P = 0.015) and distant recurrence (19.0% vs. 7.8%, P = 0.008). Multivariate analysis confirmed that pNR was an independent risk factor for poor OS (HR 1.926; 95% CI 1.250-2.970; P = 0.003) and DFS (HR 1.899; 95% CI 1.300-2.775; P = 0.001). Lymphovascular invasion (LVI) and perineural invasion (PNI) were independent risk factors for pNR (both P<0.001). Within the pNR subgroup, the PNI and ypN2/N3 stage were independent prognostic factors for poor survival (all P<0.05). Conclusion: pNR to NACI strongly predicts worse outcomes in LA-ESCC patients. LVI and PNI are key risk factors, with PNI or advanced ypN stage further defining a high-risk pNR subgroup warranting aggressive postoperative management and surveillance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.